Antifungal Use in Oncohematological Neutropenic Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00386802 |
Recruitment Status :
Completed
First Posted : October 12, 2006
Last Update Posted : September 18, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Primary purpose: Frequency of use of broad-spectrum antifungals in the episode of neutropenia.
Secondary purposes:To determine the safety and toxicity measure by:
- Frequency of Invader Fungal Infection.
- Frequency of global use of broad-spectrum antifungals as amphotericine, itraconazole, voriconazole, caspofungin, terbinafine, during the period of study.
- Mortality
- Development of nephrotoxicity
- Use of galactomannan in this clinical context
- Time of administration of empirical antifungal therapy of broad-spectrum.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Invader Fungal Infection | Drug: Antifungal drug. VORICONAZOL. (VFEND®) | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 115 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | ANTIVORIFUNGOL:Strategy of Antifungal Use in Oncohematological Neutropenic Patients. Use of Voriconazole as Early Treatment. |
Study Start Date : | August 2006 |
Actual Primary Completion Date : | December 2008 |
Actual Study Completion Date : | January 2009 |

- Drug: Antifungal drug. VORICONAZOL. (VFEND®)
I.V charge dose 6 mg/kg/12h (2 doses) Maintenance iv treatment 4 mg/kg/12h during 6 days, followed by oral treatment (200 mg/12h)
- Frequency of use of broad-spectrum antifungals in the episode of neutropenia. [ Time Frame: 2 years ]
- To determine the safety and toxicity measure by: [ Time Frame: 1 year ]
- Frequency of Invader Fungal Infection. [ Time Frame: 2 years ]
- Frequency of global use of broad-spectrum antifungals as amphotericine, itraconazole, voriconazole, caspofungin, terbinafine, during the period of study. [ Time Frame: 2 years ]
- Mortality [ Time Frame: 2 years ]
- Development of nephrotoxicity [ Time Frame: 2 years ]
- Use of galactomannan in this clinical context [ Time Frame: 2 years ]
- Time of administration of empirical antifungal therapy of broad-spectrum. [ Time Frame: 6 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 2 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adult and pediatric patients (from 2 years old on) with diagnostic of hematologic malignancies or solid tumour.
- Patients who will develop neutropenia (<500PN) post chemotherapy or post Bone Marrow Transplantation (BMT) that according to the center, they can receive empirical antifungal treatment of broad-spectrum.
- Controlled patients with galactomannan in blood twice weekly.
- Empirical antibacterial therapy of broad-spectrum, as possible the Pethema protocol that it is activated in this moment. Also it will be validated the monotherapy with carbapenemic or cephalosporin of fourth or third generation, or the biotherapy.
- Inclusion of patient since the start of his chemotherapy or therapy of preparation.
- If a bacterial infection is documented, it will be treated and controlled before to begin the empirical antifungal treatment.
- Signed of informed consent.
- Negative pregnancy test in fertile patients
Exclusion Criteria:
- Use of antifungal prophylaxis with triazoles with activity against Aspergillus, or use of others systematics antifungal by previous Invader Fungal Infection or other reasons.
- Use prophylactic of fluconazole to dose higher than 100 mg/day.
- Allergy to azoles
- To have a invader fungal infection at start of episode of neutropenia with fever.
- High effect in the unity of insulation of Candida strong to fluconazole that to opinion of center it hasn´t appropriate to include in a protocol where it is considered the use of empirical fluconazole.
- Neutropenias made by aplastic anemia or other faults of bone similar.
- Inclusion previous in this study.
- The patients will be excluded if they have settled by Aspergillus, C.krusei or C.gladiata in this episode of neutropenia, or in other and if they lack of the results of the cultures of vigilance in the present episode. If it presents positive result for any of those pathogens the empirical treatment will must be with a antifungal that it covers good (amphotericin, caspofungin or voriconazole) and not with fluconazole, then those patients will not follow this protocol.
- To receive drugs, which aren´t indicated in patients in treatment with voriconazole and/or with fluconazole.
- The patients will not be excluded if they receive antibacterial prophylaxis oral with quinolones, macrolides, etc., or stimulating factors G-CSF, GM-CSF or similar.
- Cause of exclusion will be the fault of fulfilment of inclusion criteria. Above all the patients will be excluded if they:
- have fault of twice weekly monitoring with galactomannan.
- have a bacterial infection not very good treated and controlled before to can begin the empirical antifungal infection (according to definition previous)
- have at final, a neutropenia of short stay that it has a risk important of Invader Fungal Infection. This data naturally will not know in the moment of include at patient in the study. It defines as neutropenia of short stay if it last out less of 5 days.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00386802
Spain | |
Hospital General de Jerez de la Frontera | |
Jerez de la Frontera, Cádiz, Spain | |
Hospital Son Llatzer | |
Palma de Mallorca, Mallorca, Spain | |
Hospital Clínic | |
Barcelona, Spain | |
Hospital Virgen de las Nieves | |
Granada, Spain | |
Hospital General Universitario Gregorio Marañón, Madrid | |
Madrid, Spain | |
Hospital Universitario de la Princesa | |
Madrid, Spain | |
Hospital Universitario Ramón y Cajal, Madrid | |
Madrid, Spain | |
Hospital Universitario Morales Meseguer, Murcia | |
Murcia, Spain | |
Hospital Clínico Universitario de Salamanca | |
Salamanca, Spain | |
Hospital Universitario Marqués de Valdecilla | |
Santander, Spain | |
Hospital Clínico Universitario de Valencia | |
Valencia, Spain | |
Hospital Universitario La Fe | |
Valencia, Spain | |
Hospital Clínico Lozano Blesa | |
Zaragoza, Spain |
Principal Investigator: | de la Cámara Rafael, Dr | Hospital Universitario de la Princesa, Madrid |
Publications:
Responsible Party: | Pethema, pethema |
ClinicalTrials.gov Identifier: | NCT00386802 |
Other Study ID Numbers: |
2005-004973-55 ANTIVORIFUNGOL |
First Posted: | October 12, 2006 Key Record Dates |
Last Update Posted: | September 18, 2009 |
Last Verified: | September 2009 |
Neutropenia Antifungals |
Mycoses Antifungal Agents Clotrimazole Miconazole Anti-Infective Agents Anti-Infective Agents, Local 14-alpha Demethylase Inhibitors Cytochrome P-450 Enzyme Inhibitors |
Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Steroid Synthesis Inhibitors Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Cytochrome P-450 CYP2C9 Inhibitors Cytochrome P-450 CYP3A Inhibitors |